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Purpose: T-helper 17 lymphocytes (Th17) were identified in the healthy conjunctiva and in patients with ocular cicatricial
pemphigoid (OCP), a disease characterized by chronic ocular surface inflammation.
Methods: Conjunctival biopsies and blood samples were obtained from 10 patients with OCP (4 males, 6 females; 57–
90 years of age) and 6 age/sex matched healthy subjects. Conjunctival samples were immunostained with anti-human
IL17/CD4 antibodies and stained cells were then counted by confocal microscopy in three 60X field images per each
sample. Mononuclear cells were isolated from both OCP and healthy blood samples and evaluated for IL17 and CD4 by
FACS. IL17, TGF-β, IL4, and IFN-γ levels were determined in plasma of OCP and healthy patients by ELISA.
Results: The presence of Th17 lymphocytes in conjunctival biopsies was significantly (p<0.05) increased in patients with
OCP (14.9±12.8 cells per microscopic field) compared to healthy subjects (0.5±0.8 cells per microscopic field). Th17
lymphocytes comprised 72% of CD4+ cells in four stage-III OCP conjunctival samples. No significant difference was
observed for IL17 in peripheral blood of OCP versus healthy subjects.
Conclusions: In this study, we report an increased localization of Th17 lymphocytes in OCP conjunctiva, not accompanied
by similar findings in peripheral blood. This finding suggests an increased recruitment of Th17 lymphocytes in conjunctiva
and/or a dysfunctional local immune response in the chronically inflamed conjunctiva of OCP. Our findings are in line
with previously reported evidence demonstrating that Th17 cells play a critical pathogenic role in mucosal autoimmunity.
The family of CD4+ T-cells includes different subtypes
of  T-helper  (Th)  lymphocytes  characterized  by  specific
cytokine profiles: Th1 cells secrete IFNγ and IL-2; Th2 cells
secrete IL-4, IL-5, and IL-13; and Th17 cells secrete IL-17
[1-5]. Recently, Th17 lymphocytes have been characterized
as  potent  inducers  of  tissue  inflammation  in  several
autoimmune diseases, such as inflammatory bowel disease
(IBD),  psoriasis,  multiple  sclerosis  (MS),  lupus
erythematosus  systemicus,  rheumatoid  arthritis  (RA),  and
Bechet’s disease, through the activation of a wide range of
inflammatory mediators (IL-6 and IL-8), angiogenesis, and
the  induction  of  immune  cell  activation,  particularly
neutrophils [6-15]. In fact, increased levels of IL-17 have been
detected in biopsies of skin from psoriasis patients, of gut from
IBD patients, of brain from MS patients, and of the synovium
as well as synovial fluid from RA patients [16]. IL-17 was in
fact associated with an increase in both activity and severity
of  these  diseases  [17,18].  Concordant  results  have  been
obtained in mouse models of RA, in which the local release
of  IL-17  induces  massive  damage  with  extensive
inflammatory  cell  migration,  bone  erosions,  and  cartilage
degradation [19].
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These data indicate a pivotal role of Th17 in regulating
the mucosal immune response through migration of immune
cells  to  target  organs  and  induction  of  pro-inflammatory
cytokine  release,  ultimately  leading  to  tissue  damage.
However, to date the role of Th17 in ocular inflammatory
diseases has been studied only in uveitis and scleritis [12,
20-22].
In this study, we investigated the role played by Th17
lymphocytes  in  ocular  cicatricial  pemphigoid  (OCP),  an
autoimmune  disease  characterized  by  chronic  mucosal
inflammation  with  T-cell  dysfunction  and  infiltration  of
immune cells in the conjunctiva [23-25].
METHODS
Patients  and  biological  sample  handling:  The  study  was
performed in accordance to the tenets of the Declaration of
Helsinki  for  research  involving  human  subjects  and  the
Intramural Ethics Committee approved the project. Informed
consent was signed by each participant.
Biopsies  from  temporal  bulbar  conjunctiva  and
peripheral blood samples were obtained from 10 patients with
OCP (4 males, 6 females; 57–90 years of age) and 6 age/sex
matched healthy subjects with no history of dry eye or other
ocular  diseases  at  the  time  of  cataract  surgery.  Healthy
subjects were carefully screened for dry eye by rose bengal/
fluorescein staining and lacrimal functional tests including
tear osmolarity, Schirmer tests, and Tear Film Break-up time
test. Table 1 shows the main clinical characteristics of the OCP
Molecular Vision 2009; 15:1449-1455 <http://www.molvis.org/molvis/v15/a154>
Received 29 May 2009 | Accepted 24 July 2009 | Published 28 July 2009
© 2009 Molecular Vision
1449patients recruited for this study at the time of the first visit to
our Cornea and External Eye Disease Unit (Campus Bio-
Medico University of Rome, Italy). The diagnosis of OCP was
based on history, clinical diagnosis, and specific linear direct
immunofluorescent labeling of conjunctival basal membrane
(Figure 1) [26]. The stage of disease was defined according to
the Foster-Mondino classification [27,28]: eight OCP patients
recruited for this study were in stage III, one patient was in
stage II and one in stage I (Table 1).
Each conjunctival biopsy was 10% formalin fixed and
processed  for  light  (histology)  or  confocal  microscopy
(immunofluorescence). Blood samples (10 ml) were collected
in  heparinized  vacutainer  vials  and  processed  for  flow
cytometry (enriched peripheral blood mononuclear cells) and
ELISA (plasma).
All  analytical  grade  reagents  and  plasticware  were
purchased from SERVA (Weidelberg, Germany) and NUNC
(Roskilde, Denmark), unless specified differently in the text.
Light  and  confocal  microscopy:  Paraffin-embedded
conjunctival biopsies were serially sliced into 5 μm sections,
attached  to  pretreated  slides  (Bioptica,  Milan,  Italy)  and
processed for either basic histology (hematoxylin and eosin;
Bioptica)  or  direct  immunofluorescence,  according  to
standardized procedures.
Direct immunofluorescence on conjunctival biopsies was
performed to demonstrate OCP conjunctival basal membrane
positivity  to  goat  anti-human  FITC-conjugated
immunoglobulin  (AbD  Serotec,  Oxford,  UK).  To  identify
IL-17 and CD4 positive cells, immunofluorescence staining
was performed. Endogenous peroxidase signal was quenched
by incubation in 3% H2O2 for 5 min and 50 mM NH4Cl for
2min; antigen was then retrieved by enzymatic pretreatment
TABLE 1. MAIN CLINICAL CHARACTERISTICS OF THE OCP PATIENTS RECRUITED FOR THIS STUDY.
Foster
classification
[29,30] Cornea
Schirmer
test I 
5 min
Disease
activity Topical therapy
1 90 M III SPK 2 quiescent steroids
2 49 F III SPK 4 active artificial tears
3 57 F III band keratopathy 9 active artificial tears
4 69 M III leucoma 5 quiescent artificial tears
5 60 M II leucoma, SPK 1 active artificial tears
6 63 F I SPK 2 quiescent artificial tears
7 76 F III SPK 5 quiescent artificial tears
8 83 M III SPK 4 active steroids
9 79 F III band keratopathy 0 quiescent artificial tears, steroids
10 68 F III SPK 2 active artificial tears
In the table, SPK indicates superficial punctate keratitis.
Figure 1. Histology of OCP conjunctiva. OCP conjunctiva was infiltrated with immune cells, including lymphocytes, plasma cells and
leukocytes  (A),  whereas  healthy  conjunctiva  was  free  of  immune  cells  (B).  A  linear  direct  immunofluorescence  labeling  (green)  of
autoantibodies in the conjunctival basal membrane was observed in all OCP samples (insert A). No immunostaining was observed in control
samples (insert B).
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mm/ ID Age Genderwith  hyaluronidase  (1mg/ml,  in  sodium  acetic  acid;  ICN,
Costa Mesa, CA). A brief blocking/permeabilizing step was
performed for 20 min (0.8% BSA, BSA-0.3% Triton X-100
[TX]  in  10  mM  phosphate-buffered  saline,  PBS)  before
addition  of  the  specific  PE  conjugated  antihuman  IL-17
antibodies (2 μg/ml; eBioscience, San Diego, CA), PE-Cy5.5-
conjugated antihuman CD4 antibodies (2 μg/ml), or irrelevant
isotype-matched IgG antibodies (eBioscience), as negative
controls for staining specificity, diluted in 0.1% Tween-20-
PBS. Sections of human nasal turbinates were used as positive
controls for the internal procedure (data not shown) [29].
Antifade/gel  (Vector,  Burlingame,  CA)  mounted  sections
were examined at 60X magnification in oil immersion using
an E2000U three-laser confocal microscope equipped with C1
software (Nikon, Tokjo, Japan).
Three optic fields per each section (3 slides per patient)
were  acquired  randomly  in  a  masked  fashion  by  an
independent observer and digitalized using Adobe Photoshop
7.0  (Adobe,  San  Jose,  CA)  software.  Cell  counts  were
performed by two independent observers. Each observer was
blinded to the decision of the other observer [30-32].
Flow  cytometry:  Peripheral  blood  mononuclear  cells
(PBMNCs) of OCP patients and controls were obtained from
heparinized-whole  blood  samples,  following  gradient
selection  (lympholyteTM;  Euroclone,  Milan,  Italy),
according to a standardized procedure. Red cells were lysed
(RBC Gentra solution; Qiagen, Mila, Italy) and white cells
were  directly  stored  in  liquid  nitrogen  for  the  following
experiments.  Direct  immunostaining  was  performed  with
phycoerythrin (PE)-conjugated antihuman IL17A (0.25 µg/
106 cells; ebioscience) and PE-Cy5-conjugated antihuman
CD4 (both at 0.25 µg/106 cells; ebioscience), according to the
manufacturer's  instructions.  All  samples  were  analyzed
through a FACSCalibur flow cytometer (Becton Dickinson,
Milan, Italy) equipped with an argon laser emitting at 488 nm
and  three  band-pass  detectors.  Forward  and  side  scatter
signals were collected as linear signals, and all emissions were
evaluated on a four-decade logarithmic scale. PE and PE-
Cy5.5 signals were measured, respectively at 575 nm and 670
nm.  Spectral  overlap  was  minimized  by  electronic
compensation  before  each  series.  CellQuest®  software
(Becton Dickinson) was used to acquire and evaluate 5,000
events with preserved side scatter signals and high membrane
Figure 2. Immunolocalization of Th17 cells in OCP conjunctiva. Th17 lymphocytes were labeled with PE-conjugated anti-human IL-17
antibodies (red). Increased Th17 staining was observed in OCP (A) compared to healthy subjects (B). Double-staining for CD4 (C, blue) and
IL17 (D, red) performed on four stage-III OCP samples demonstrated that 72% of CD4+ T cells were Th17 lymphocytes (Merged image E,
violet).
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1451staining for specific antibodies [33]. Data were expressed as
% of positive cells or mean fluorescence intensity, calculated
as  follows:  ΔMFI=(specific  MFI-aspecific  MFI)/aspecific
MFI.
ELISA assay: To evaluate IL-17, TGF-β, IL-4, and IFN-γ in
plasma collected from heparinized peripheral blood of OCP
patients  and  controls,  we  performed  a  two-site  ELISA
(sensitivity=0.5 pg/ml) using commercially available kits and
following  the  manufacturer’s  instructions  (eBioscience).
Optical  density  (OD)  was  measured  at  λ450–550  by  a
microplate ELISA reader (Sunrise; Tecan Systems, Inc., San
Jose, CA).
Statistical  analysis:  All  experiments  were  performed  in
duplicate  and  results  are  expressed  as  the  mean±standard
deviation  of  the  mean  (SD).  Statistical  analyses  were
performed using ANOVA followed by Tukey-Kramer post-
hoc  calculations.  Analyses  were  performed  using  the
statistical package StatView II for PC (Abacus Concepts Inc.,
Berkley,  CA).A  p  value  less  than  0.05  was  considered
statistically significant.
RESULTS
All  ten  OCP  conjunctival  samples  (100%)  showed  the
presence of Th17 lymphocytes, as compared to only two of
six healthy subjects (33%). Moreover, the number of Th17
lymphocytes was significantly increased in OCP compared to
controls (14.9±12.8 versus 0.5±0.8, p<0.05; Figure 2 A-B).
Histological analysis showed that the conjunctiva of OCP
patients was infiltrated by immune cells comprised for the
most  part  by  lymphocytes,  plasma  cells  and  leukocytes
(Figure 1). Since T-helper lymphocytes play a major role in
the  pathogenesis  of  OCP,  the  conjunctival  lymphocyte
infiltrate was characterized by immunostaining. CD4+ cells
were  significantly  increased  in  OCP  compared  to  healthy
conjunctiva (14.7±6.3 versus 4.2±2.1, respectively, p<0.05).
Interestingly,  as  shown  in  Figure  2  C-E,  double-
immunofluorescence  of  four  stage-III  OCP  conjunctival
samples revealed that 72% (range 57%–82%) of the CD4+
cells were of the Th17 type.
Since  OCP  is  a  systemic  autoimmune  disease,  the
presence of Th17 was also investigated in peripheral blood
samples together with the circulating cytokine profile. Flow
cytometry results showed that circulating T-helper and Th17
lymphocytes in peripheral blood were not changed in patients
affected by OCP (Figure 3). The analysis of IL17-specific
immunofluorescence also showed no significant difference
between OCP patients and healthy subjects (MFI: 14.8±4.5
versus MFI: 17.1±3.2, ΔMIF: 2.3; p>0.05).
These results were confirmed by ELISA data regarding
circulating cytokines (Figure 4). No significant differences in
plasma  IL-17  (518.2±75  pg/ml  versus  466.1±92  pg/ml;
p>0.05),  IL-4  (57.7±8.4  pg/ml  versus  56.8±10.8  pg/ml;
p>0.05) or TGF-β (747.4±342.6 pg/ml versus 759.7±126.5
pg/ml; p>0.05) were observed between patients with OCP and
healthy  subjects.  Conversely,  a  significant  increase  of
circulating  IFNγ  was  observed  in  patients  with  OCP
(792.7±104.5 pg/ml versus 556.7±184 pg/ml; p<0.05).
DISCUSSION
In  this  study,  we  demonstrate  that  Th17  lymphocytes  are
present in OCP conjunctiva, and are significantly increased
Figure 3. Th lymphocytes in peripheral blood. In peripheral blood,
the expression of T-helper lymphocytes (CD4+) and Th17 (IL17+)
was determined quantitatively with cytofluorimetry. No significant
differences were observed in CD4+ or Th17 expression in 10 patients
with OCP versus 6 healthy subjects (data are expressed as cells
percentage±SD).
Figure 4. Cytokines in peripheral blood. ELISA results revealed that
there was no significant difference in IL-17, IL-4 or TGF-β plasma
levels in patients with OCP versus healthy subjects. A significant
increase of circulating IFNγ was observed in patients with OCP. Data
are expressed as mean±SD.
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1452compared to healthy controls. Moreover, Th17 comprises the
primary subtype of immune cells infiltrating the conjunctiva
of OCP patients (more than 70% of CD4+ cells in disease stage
III). These data are in line with previous results reported in
other human autoimmune diseases, in which a local increase
of Th17/IL-17 plays a crucial role in mucosal autoimmunity
[19]. It is also worth noting that the predominant Th17 CD4+
subtype in our study was found in the long-standing cases of
OCP (mean time from onset of disease: 4 years, range 3–9
years), suggesting that CD4+ Th17 mucosal infiltration could
be a marker of chronic inflammatory states of the conjunctiva.
Supporting the hypothesis that Th17 lymphocytes may be
responsible for a dysfunctional local immune response in the
chronically inflamed OCP conjunctiva, several studies have
shown  that  IL-17-producing-Th17  cells  play  a  critical
pathogenic role in autoimmunity, promoting organ-specific
damage  in  several  autoimmune  diseases  such  as  uveitis,
Sjögren’s,  MS,  IBD,  RA,  etc  [10,34-40].  In  addition,  the
involvement of Th17 in the pathogenesis of OCP confirms
previous  observations  on  the  anti-inflammatory  effects  of
macrolides in this disease through inhibition of IL-17-induced
IL-8 production [41,42].
In our study Th17 cells were also found in the circulation
in  both  OCP  and  healthy  subjects,  where  they  comprise
approximately 10% of CD4+ T lymphocytes. The apparent
discrepancy  that  we  observed  between  conjunctival  and
peripheral Th17 involvement in OCP may be explained by
either  a  specific  Th17-driven  local  response  in  the
conjunctiva,  or  an  increased  Th17  homing  to  the  ocular
surface. In line with this hypothesis, Kleinscheck et al. [43]
recently demonstrated that Th17 cells are imprinted for gut
homing, and mediate destructive tissue inflammation in IBD.
IFNγ stimulation of local Th17 trafficking may also justify the
unchanged circulating number of these cells observed in the
OCP patients enrolled in our study [44,45]. Our finding of
increased circulating IFNγ associated with normal levels of
IL17  is  in  line  with  previous  reports  showing  that  IFNγ
antagonizes Th17 cell development, and allows speculating
that overexpression of IFNγ in OCP patients could provoke a
compensatory mechanism that ameliorates autoimmune tissue
damage [46].
The findings of this study suggest a role of Th17 cells in
the  pathogenesis  of  OCP.  Identification  of  novel  immune
targets such as this provide focus to the search for a more
effective therapeutic strategy in OCP. Th17 has already been
targeted in other autoimmune diseases and preliminary data
indicate that inhibition of Th17 might cure IBD in animal
models [47].
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